MedTrace Logo

Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

NCT05642949 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2023-01-09

No results posted yet for this study

Summary

This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

MHB036C

MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).

Sponsors & Collaborators

  • Minghui Pharmaceutical Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-23
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642949 on ClinicalTrials.gov